Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Alexander Hindenburg is active.

Publication


Featured researches published by Alexander Hindenburg.


Frontiers in Oncology | 2013

Coronary Calcium Scanning in Patients after Adjuvant Radiation for Early Breast Cancer and Ductal Carcinoma In situ.

Monique Chang; Jason Suh; Vatsala Kirtani; Andrei Dobrescu; J.A. Haas; Steven M. Zeldis; Steven Shayani; Alexander Hindenburg

Background and Objective: Radiation therapy (RT) is part of standard adjuvant treatment for breast cancer. Earlier studies demonstrated increased cardiac morbidity and mortality from this. Coronary Calcium scanning utilizing Multidetector Computed Tomography (MDCT) can detect early atherosclerosis in coronary arteries by identifying the amount of calcifications. In our study we employed these tools to detect occult atherosclerosis at least 5 years following breast RT. Methods: We evaluated 20 asymptomatic patients, <60 years old, treated with RT at least 5 years prior to enrollment. Nine received RT to the left and 11 to the right chest wall. The median interval between RT and calcium scan was 8 years. All patients were treated with external beam RT using tangential technique. All patients underwent MDCT to compute volumetric and Agatston calcium scores of the coronary arteries and the aorta. Results: Eleven patients had RT to the right chest wall, and eight had a calcium score of 0, while two had minimally elevated scores and one patient had a significantly elevated score. Meanwhile nine patients had RT to the left chest wall, and seven had a calcium score of 0. None had significantly elevated scores. In the aorta, 11 of 20 patients had a score of 0, while 8 of 20 had minimally elevated scores. Conclusion: In contrast to studies demonstrating increased cardiovascular morbidity, our pilot study did not detect significant occult atherosclerosis using MDCT of the coronaries and aorta of patients assessed five or more years following radiation for treatment of breast cancer.


Cancer Chemotherapy and Pharmacology | 1991

Membrane glycoprotein changes associated with anthracycline resistance in HL-60 cells.

James E. Gervasoni; Robert N. Taub; Michelle Rosado; Sindu Krishna; Valerie J. Stewart; Daniel M. Knowles; Kapil N. Bhalla; Douglas D. Ross; Michael A. Baker; Jose Lutzky; Alexander Hindenburg

SummaryThe glycoproteins on the surface of HL-60/S wild-type, drug-sensitive human leukemia cells and HL-60/AR anthracycline-resistant cells which do not overexpress the P-glycoprotein, were characterized by labeling with [35S]-methionine, NaB[3H4], phosphorus 32, or sodium iodide I 125. HL-60/S and HL-60/AR cell lysates and membrane fractions tagged with [35S]-methionine or phosphorus 32 showed no significant differences in their protein patterns as analyzed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and by autoradiography. HL-60/S cells labeled with NaB[3H4] yielded glycoproteins that were smeared predominantly in the molecular-weight range of 210,000 and 160,000 Da, with pI values ranging between pH 4 and pH 4.4. In contrast, NaB[3H4]-labeled HL-60/AR cells showed 7–8 discrete glycoproteins within a molecular-weight range of 170,000 and 140,000 Da, with pI values also ranging between pH 4 and pH 4.4. In addition, [3H]-glucosamine incorporation into HL-60/S and HL-60/AR cells revealed that the latter showed lower uptake of [3H]-glucosamine than did the former. Following treatment with tunicamycin, [3H]-glucosamine uptake in HL-60/S cells decreased, whereas that in HL-60/AR cells remained unchanged. Surface-membrane radioiodination of HL-60/S and HL-60/AR cells showed two distinct protein electrophoretic patterns, with differences being observed in both the high-(220–95 kDa) and low-molecular-weight ranges (21 kDa). Flow cytometric analysis of HL-60/S and HL-60/AR cells using myeloid and lymphoid antigen-specific antibodies demonstrated no antigenic differences between HL-60/S and HL-60/AR cells. HL-60/S cells incubated in the presence of tunicamycin, an inhibitor ofN-linked glycosylation, or the protein kinase C agonist phorbol 12-myristate 13-acetate (PMA) developed a glycoprotein pattern similar to that observed in HL-60/AR cells. In addition, tunicamycin treatment of HL-60/S cells decreased daunorubicin (DNR) retention and altered its intracellular distribution as compared with that in HL-60/AR cells. These data indicate that HL-60/AR cells do not possess either de novo or amplified high-molecular-weight surface-membrane proteins; instead, existing proteins are hypoglycosylated. These results also show that HL-60/AR cells exhibit the multidrug-resistant phenotype in association with altered membrane glycoproteins of both high (220–95 kDa) and low molecular weight (21 kDa), but without overexpression of the P-glycoprotein. Furthermore, in HL-60/S cells, the multidrug-resistant phenotype is partially inducible by inhibition ofN-linked glycosylation of cell-surfac proteins.


Scandinavian Journal of Infectious Diseases | 2014

Erdheim-Chester disease: a rare cause of recurrent fever of unknown origin mimicking lymphoma.

Anusiyanthan Mariampillai; Abirami Sivapiragasam; Amit Kumar; Alexander Hindenburg; Burke A. Cunha; Jianhong Zhou

Abstract We report the case of a patient with recurrent fever of unknown origin (FUO) with prominent back pain, hepatosplenomegaly, and abdominal/pelvic adenopathy suggesting lymphoma. A bone biopsy showed histiocytic infiltration. Studies for lymphoma were negative, but immunohistochemical stains were diagnostic of Erdheim–Chester disease (ECD). ECD should be included as a rare cause of recurrent FUO with bone involvement.


Journal of Clinical Oncology | 2018

Utilization rates of enoxaparin and heparin in venous thromboembolism prophylaxis after education and electronic order change at a single institution: A quality improvement study.

Linda Phuong Hoang; Alexander Hindenburg

e18836Background: Despite data demonstrating an advantage of enoxaparin (LMWH) over heparin (UFH) for venous thromboembolism (VTE), an analysis of hospital prescribing trends showed use of each was...


Cancer Research | 1991

Subcellular Distribution of Daunorubicin in P-Glycoprotein-positive and -negative Drug-resistant Cell Lines Using Laser-assisted Confocal Microscopy

James E. Gervasoni; Scott Z. Fields; Sindu Krishna; Michael A. Baker; Michelle Rosado; Kalpna Thuraisamy; Alexander Hindenburg; Robert N. Taub


Cancer Research | 1987

Effect of Verapamil and Other Agents on the Distribution of Anthracyclines and on Reversal of Drug Resistance

Alexander Hindenburg; Michael A. Baker; Elizabeth Gleyzer; Valerie J. Stewart; Norris Case; Robert N. Taub


Blood | 1994

Identification of a malignant counterpart of the monocyte-dendritic cell progenitor in an acute myeloid leukemia

F Santiago-Schwarz; Dl Coppock; Alexander Hindenburg; J Kern


Blood | 1985

Increased activity of a specific sialyltransferase in chronic myelogenous leukemia.

Michael A. Baker; Robert N. Taub; Kanani A; Brockhausen I; Alexander Hindenburg


Blood | 1984

Aberrant sialylation of granulocyte membranes in chronic myelogenous leukemia

Michael A. Baker; Robert N. Taub; Ch Whelton; Alexander Hindenburg


Cancer Research | 1985

Effects of Pyrimidine Antagonists on Sialic Acid Regeneration in HL-60 Cells

Alexander Hindenburg; Robert N. Taub; Steven Grant; George J. Chang; Michael A. Baker

Collaboration


Dive into the Alexander Hindenburg's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jason Suh

Winthrop-University Hospital

View shared research outputs
Top Co-Authors

Avatar

Jennifer Kujawa

Winthrop-University Hospital

View shared research outputs
Top Co-Authors

Avatar

Amishi Desai

Winthrop-University Hospital

View shared research outputs
Top Co-Authors

Avatar

Josephine Dela Cruz

Winthrop-University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Monique Chang

Winthrop-University Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge